Ge Long Hui·2025-12-10 09:38Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the National Medical Products Administration for its new drug, SPH3127 tablets, which are a new generation of oral non-peptide small molecule renin inhibitors for the treatment of primary hypertension [1] Company Summary - The drug SPH3127 is designed to directly inhibit renin, counteracting the increase in blood pressure caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - The approval of SPH3127 represents a significant advancement in the company's product offerings in the hypertension treatment market [1] Industry Summary - The approval of new hypertension treatments like SPH3127 reflects ongoing innovation in the pharmaceutical industry, particularly in the development of targeted therapies for cardiovascular conditions [1] - The introduction of non-peptide small molecule inhibitors may enhance treatment options for patients with primary hypertension, potentially impacting market dynamics [1]